Opinion & analysis

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

Although original estimates put staff losses at the European Medicines Agency at about 19% due to the EMA’s relocation from London to Amsterdam, the EMA reports that these losses may actually be much higher, forcing the agency to take a hard look at its most pressing priorities moving forward.

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

Next-Generation Roche: How Data Analytics Will Keep It In The Lead In Oncology

Cosmetic Preservatives Crisis Creeping Into CIR Program

Paying For Gene Therapy: Will Pharma Be First In Line?

New Reasons Not To Use EU MDR’s Four-Year Extension, But Comply Earlier Or Retire Products Instead

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

Bayer’s US Playbook: The Smart Way To Top-Line Growth

Pharma’s New R&D Models: Federating Innovation

The Blockbusters No One Talks About

It’s Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims

Thinking about using CMMI? Here are tips from the experts

J&J Scores Early In ‘Hypoallergenic’ Case; Plaintiff’s Definition ‘Implausible,’ Court Says

NASH: Flying The Plane While Building It

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

Moving Medical Affairs To The Pharma Forefront